Carnegie Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CARNEGIE
CARNEGIE has eighteen approved drugs.
Drugs and US Patents for Carnegie
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Carnegie | CLINDAMYCIN PHOSPHATE | clindamycin phosphate | SWAB;TOPICAL | 219612-001 | Jun 13, 2025 | AT | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Carnegie | ERY-TAB | erythromycin | TABLET, DELAYED RELEASE;ORAL | 062298-002 | Approved Prior to Jan 1, 1982 | AB | RX | No | Yes | ⤷ Start Trial | ⤷ Start Trial | ||||
| Carnegie | LATANOPROST | latanoprost | SOLUTION/DROPS;OPHTHALMIC | 202077-001 | Feb 11, 2013 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Carnegie | FAMOTIDINE | famotidine | FOR SUSPENSION;ORAL | 217137-001 | Jul 7, 2023 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |

